Quarterly report pursuant to Section 13 or 15(d)

Unaudited Condensed Consolidated Statements of Operations

v3.21.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Unaudited Condensed Consolidated Statements of Operations        
Product revenue, net $ 19,610 $ 9,447 $ 45,617 $ 30,808
Operating expenses        
Cost of goods sold - product revenue 11,167 3,379 22,559 10,313
Research and development 718   747  
Research and development-licenses acquired, expense 76   13,819  
Selling, general and administrative 10,755 5,829 24,776 16,270
Wire transfer fraud loss 9,540   9,540  
Total operating expenses 32,256 9,208 71,441 26,583
(Loss) income from operations (12,646) 239 (25,824) 4,225
Other expense        
Interest expense 1,373 187 2,936 492
Change in fair value of derivative liability 2   184  
Total other expense 1,375 187 3,120 492
Net (loss) income before income taxes (14,021) 52 (28,944) 3,733
Income tax (benefit) expense (3,375) 23 (6,701) 952
Net (loss) income $ (10,646) $ 29 $ (22,243) $ 2,781
Net (loss) income per common share - basic $ (1.16) $ 0.00 $ (2.43) $ 0.30
Net (loss) income per common share - diluted $ (1.16) $ 0.00 $ (2.43) $ 0.26
Weighted average common shares outstanding - basic 9,161,333 9,133,333 9,160,344 9,133,333
Weighted average common shares outstanding - diluted 9,161,333 10,800,475 9,160,344 10,817,678